Spotlight On... inVentiv opens new Phase I clinic; Pfizer taps Adaptive for immunotherapy R&D; and much more...

CRO inVentiv Health is expanding its early-stage research capabilities, opening a new Phase I clinic in Florida. The facility, sited at the University of Miami Life Science and Technology Park, has room for 44 beds, complementing inVentiv's existing Phase I-IV services around the U.S., the company said. More

> Pfizer ($PFE) signed a deal with Adaptive Biotechnologies to use the company's genomic sequencing technology in its efforts to develop immuno-oncology therapies. News

> The Indian CRO market has plenty of room to grow, according to the departing CEO of Biocon's Syngene. Story

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.